Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...

Incontinence is big business—Boston Scientific valued (PDF) the prosthetic urology and pelvic floor markets at a combined $1.1 billion last year—but could be bigger if more men were aware of ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Boston Scientific shares fell Wednesday as its third ... The MedSurg division, which includes endoscopy, urology, and neuromodulation devices, had a 10% revenue rise to $1.48 billion.

Boston Scientific Corp. engages in the development ... The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral ...